Gentherm announces Q3 adjusted EPS of 73 cents, surpassing consensus estimate of 65 cents.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Oct 23 2025
0mins
Should l Buy THRM?
Q3 Financial Performance: Reports Q3 revenue of $386.87M, exceeding consensus estimates of $375.15M, indicating strong financial and operational performance.
New Business Awards: Secured $745M in Automotive New Business Awards, on track to exceed $2B for the year, reflecting ongoing commercial momentum.
Market Growth: Improved growth over market with new program launches and increased take rates in the China market, contributing to operational excellence.
Strategic Initiatives: Expanded into adjacent markets, such as furniture, showcasing confidence in scaling core technologies for profitable growth and long-term value creation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy THRM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on THRM
Wall Street analysts forecast THRM stock price to rise
4 Analyst Rating
2 Buy
2 Hold
0 Sell
Moderate Buy
Current: 32.770
Low
42.00
Averages
43.33
High
44.00
Current: 32.770
Low
42.00
Averages
43.33
High
44.00
About THRM
Gentherm Incorporated is a provider of thermal management and pneumatic comfort technologies. The Company operates in two segments: Automotive and Medical. The Automotive reporting segment comprises global automotive businesses, including the design, development, manufacturing and sales of its automotive climate and comfort solutions (including Climate Control Seats, Climate Control Interiors, lumbar and massage comfort solutions and electronic solutions for climate and comfort technologies), valve system solutions and other automotive products. The Medical reporting segment comprises the patient temperature management business in the medical industry. Patient temperature management includes temperature management systems across multiple product categories addressing the needs of hyper-hypothermia therapy in intensive care, normothermia in surgical procedures and additional warming/cooling therapies utilized in acute and chronic care departments and non-hospital facilities.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives that could influence investor decisions.
- Market Dynamics: As analysts revise their outlook on THRM stock, investors may consider buying or selling, potentially impacting its market performance and liquidity, thereby increasing market uncertainty.
- Impact of Rating Changes: Changes in analyst ratings often have a direct effect on stock prices, prompting investors to closely monitor these shifts to timely adjust their investment strategies and optimize their portfolios.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, and investors should reference these ratings for a more comprehensive market view.
See More
- Strategic Expansion: Gentherm's planned merger with Modine Performance Technologies is expected to elevate its market size from $2.6 billion to over $3.5 billion, showcasing the company's strong potential for diversification, particularly in the medical and Home & Office sectors.
- Financial Performance: The company achieved record revenue of $1.5 billion in 2025, reflecting a 2.9% year-over-year increase, with adjusted EBITDA of $175 million, or 11.7% of sales, demonstrating stability in core operations despite foreign exchange impacts.
- Future Outlook: Management anticipates revenue for 2026 to be between $1.5 billion and $1.6 billion, representing approximately 3% growth at the midpoint, and aims for $1.7 billion in 2027, reflecting confidence in market penetration.
- Market Opportunities: Gentherm expects revenue from Home & Office and medical markets to reach between $50 million and $100 million by 2028, indicating significant growth potential in non-automotive sectors, particularly with the launch of the ThermAffyx system to accelerate medical revenue growth.
See More
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives on these companies.
- Market Reaction: While specific stocks are not mentioned, such rating changes typically influence investor decisions and may lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying CAKE stock should pay attention to the latest insights from analysts to make more informed investment decisions.
- Information Source: A complete view of all analyst rating changes can be found on Benzinga's analyst ratings page, providing comprehensive market insights and data support.
See More
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several stocks, including upgrades, downgrades, and initiations, reflecting varying market perspectives and future expectations for these companies.
- Market Dynamics: While specific stock names are not disclosed, changes in analyst ratings typically influence investor decisions and can lead to price volatility in the affected stocks.
- Investor Focus: Investors considering buying TEM stock should pay attention to the latest insights from analysts to make more informed investment decisions, especially amid increasing market uncertainties.
- Source of Information: This information is provided by Benzinga, highlighting the significance of analyst ratings in investment decisions, despite the lack of specific rating details.
See More
- Earnings Highlights: Gentherm reported a Q4 non-GAAP EPS of $0.49, missing estimates by $0.07, while revenue reached $382.8 million, an 8.5% year-over-year increase that beat expectations by $10.89 million, demonstrating resilience in the market.
- New Business Awards: The company secured automotive new business awards totaling $485 million in the quarter, further solidifying its leadership in automotive climate and comfort solutions, with production expected to commence in mid-2026.
- Product Revenue Growth: Product revenues of $382.8 million increased from $352.9 million last year, reflecting an 8.5% growth; excluding foreign currency effects, automotive revenue grew by 6.0%, while medical revenue declined by 3.9%, indicating varied performance across business lines.
- Future Outlook: Gentherm projects product revenues between $1.5 billion and $1.6 billion for 2026, with adjusted EBITDA expected to be between $175 million and $195 million, and anticipates approximately $1.7 billion in product revenues for 2027, showcasing strong growth potential.
See More
- Earnings Release Schedule: Gentherm is set to report its fourth quarter and year-end 2025 financial results on February 19, 2026, and will host a conference call at 8 AM (ET) that same day to provide detailed insights into its financial performance, aiming to enhance transparency and investor confidence.
- Conference Call Access Information: Investors can join the call by dialing 1-877-407-4018 (toll-free in the U.S.) or 1-201-689-8471 (international), with Conference ID 13758613, ensuring smooth access for investors to obtain the latest information.
- Webcast and Replay Availability: Gentherm will provide a live webcast and a one-year archived replay of the call on its Investor Relations website, allowing investors who cannot attend in real-time to access the information at their convenience, thereby enhancing information accessibility and transparency.
- Company Background Information: Gentherm is a global leader in thermal management and pneumatic comfort technologies, recording approximately $1.5 billion in sales in 2024 and securing $2.4 billion in new automotive business awards, reflecting its strong market performance and ongoing growth potential.
See More






